NK cells
NK cells is a biological therapy with 23 clinical trials. Currently 4 active trials ongoing. Historical success rate of 77.8%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
18
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
77.8%
7 of 9 finished
22.2%
2 ended early
4
trials recruiting
23
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Natural Killer Cells and Bortezomib to Treat Cancer
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma
Clinical Trials (23)
Natural Killer Cells and Bortezomib to Treat Cancer
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma
Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia
NK Cells Treatment for COVID-19
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma
Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
Effect of NK Cell Immunotherapy on Advanced Lung Adenocarcinoma Adenocarcinoma With EGFR Mutation
Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer
Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome
NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer.
A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 23